Stonebridge Capital Advisors LLC Raises Position in Eli Lilly and Company $LLY

Stonebridge Capital Advisors LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 318.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,519 shares of the company’s stock after acquiring an additional 8,003 shares during the quarter. Stonebridge Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $8,026,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of LLY. Sumitomo Mitsui Financial Group Inc. purchased a new stake in Eli Lilly and Company during the 2nd quarter worth about $27,000. Evolution Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter worth about $29,000. Steph & Co. increased its stake in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares during the period. Financial Gravity Companies Inc. acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $31,000. Finally, Bare Financial Services Inc raised its holdings in Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 29 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly launched the “Lilly Employer Connect” platform to help U.S. employers expand coverage for obesity medicines, offering flexible benefit designs and partnerships with 15+ independent program administrators; company is also offering a Zepbound (tirzepatide) KwikPen single‑patient supply at $449 across doses via the program — this aims to widen patient access while controlling employer costs, supporting uptake and recurring revenue. Lilly Employer Connect platform launches (PRNewswire)
• Positive Sentiment: Lilly confirmed an oral GLP‑1 weight‑loss drug is under evaluation by Australia’s TGA — approval of an oral formulation would broaden prescriber options and patient adoption versus injectables, potentially expanding market share in the fast‑growing obesity/GLP‑1 category. Eli Lilly confirms oral GLP‑1 being evaluated by TGA (AFR)
• Positive Sentiment: EMA issued a positive opinion for Olumiant in alopecia areata — regulatory support broadens Lilly’s immunology portfolio outside metabolic drugs, adding a new commercial avenue and diversification of growth drivers. EMA’s Positive Olumiant Alopecia Opinion (Yahoo Finance)
• Positive Sentiment: Lilly advanced remternetug testing in China and progressed a new oral diabetes candidate in China — clinical expansion in large markets strengthens long‑term neuroscience and diabetes pipelines, important for growth beyond current GLP‑1 momentum. Remternetug testing advances in China (TipRanks)
• Neutral Sentiment: Ventyx Biosciences shareholders approved a merger with Lilly — strategic bolt‑on to strengthen specific capabilities; impact depends on integration and commercialization execution. Ventyx merger approval (TipRanks)
• Neutral Sentiment: Analyst/features pieces (Zacks, 247WallSt, Motley Fool) highlight Lilly as a momentum stock amid GLP‑1 strength but debate whether investors should prefer other long‑term picks — these stories can drive short‑term interest but add little fundamental news. Zacks: Why LLY is a momentum stock

Wall Street Analysts Forecast Growth

LLY has been the subject of several analyst reports. Barclays initiated coverage on shares of Eli Lilly and Company in a report on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price target for the company. Cantor Fitzgerald lifted their price objective on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Wolfe Research increased their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. The Goldman Sachs Group set a $1,260.00 price target on Eli Lilly and Company in a research note on Thursday, February 5th. Finally, HSBC reaffirmed a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,229.59.

Eli Lilly and Company Trading Down 0.4%

Shares of LLY stock opened at $1,004.12 on Thursday. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The company has a market capitalization of $947.25 billion, a P/E ratio of 43.75, a price-to-earnings-growth ratio of 1.17 and a beta of 0.40. The business’s 50 day moving average is $1,049.25 and its two-hundred day moving average is $936.91. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter last year, the business earned $5.32 EPS. The business’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is presently 30.15%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.